Evidence map›Paper›PMID 28210825›Full record

ArticleClinical rheumatology2017

Recovery of nail dystrophy potential new therapeutic indication of tofacitinib.

Jose A Jaller, Juan J Jaller, Antonio M Jaller, Juan J Jaller-Char, Sineida Berbert Ferreira, Rachel Ferreira, Morton Scheinberg

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Clinical rheumatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jose A JallerClinica de la Piel, Departamento de Dermatologia, Barranquilla, Colombia.
Juan J JallerCentro de Reumatologia y Ortopedia, Division de Reumatologia, Barranquilla, Colombia.
Antonio M JallerClinica de la Piel, Departamento de Dermatologia, Barranquilla, Colombia.
Juan J Jaller-CharCentro de Reumatologia y Ortopedia, Division de Reumatologia, Barranquilla, Colombia.
Sineida Berbert FerreiraClinica Dermatosineida, Maringá, Brazil.
Rachel FerreiraClinica Dermatosineida, Maringá, Brazil.
Morton ScheinbergHospital Israelita Albert Einstein, Hospital AACD, São Paulo, Brazil. morton@osite.com.br.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nail dystrophy is a heterogeneous skin condition and in some subtypes, is associated with autoimmune diseases in particular psoriasis and psoriatic arthritis. In this report, we show that tofacitinib, a novel therapy for rheumatoid arthritis, appears to be beneficial in patients with nail disease refractory to other conventional modes of therapy.

Indexed as

AdultAlopeciaFemaleHumansMaleNail DiseasesPiperidinesProtein Kinase InhibitorsPyrimidinesPyrrolesTreatment OutcomePiperidinesProtein Kinase InhibitorsPyrimidinesPyrrolestofacitinibJanus kinaseNail dystrophyTofacitinib

Identifiers

PMID28210825

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.